Mechlorethamine
- Generic Name
- Mechlorethamine
- Brand Names
- Valchlor, Ledaga
- Drug Type
- Small Molecule
- Chemical Formula
- C5H11Cl2N
- CAS Number
- 51-75-2
- Unique Ingredient Identifier
- 50D9XSG0VR
- Background
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.
The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
- Indication
For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
- Associated Conditions
- Bronchogenic Carcinoma, Chronic Lymphocytic Leukemia, Hodgkins Disease (HD), Lymphoma, Diffuse, Mycosis Fungoides (MF), Polycythemia Vera (PV), Stage I Mycosis Fungoides, Malignant effusion
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: Bleomycin sulfateDrug: Stanford V regimen
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 50
- Registration Number
- NCT00002715
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.